FTRE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 22, 2026Sponsor estimate | NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult Participants | ONCLeadFTRECollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V. · APDS | FTRECollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 22, 2026Sponsor estimatePhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 3NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V. · APDSActive, not recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 31, 2026Sponsor estimate | NCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesAstraZeneca · Locally Advanced or Metastatic Solid Tumor | AZNLeadFTRECollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT07017933Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes3ive Labs · Renal Impairment After Cardiac Surgery | FTRECollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesAstraZeneca · Locally Advanced or Metastatic Solid TumorRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07017933Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes3ive Labs · Renal Impairment After Cardiac SurgeryRecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 8, 2027Sponsor estimate | NCT06495918Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular...Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration | OCULLeadFTRECollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Jan 13, 2027Sponsor estimate | NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment...AstraZeneca · Chronic Rhinosinusitis With Nasal Polyps | AZNLeadFTRECollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 8, 2027Sponsor estimatePhase 3NCT06495918Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular...Ocular Therapeutix, Inc. · Neovascular Age-related Macular DegenerationActive, not recruitingOCULLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2027Sponsor estimatePhase 3NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment...AstraZeneca · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.